πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 650 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 7524965

Dialkylphenyl compounds having Ξ²2 adrenergic receptor agonist and muscarinic receptor anta

Theravance, Inc. Β· Granted Tue Apr 28 2009 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 23 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7524962

Biphenyl compounds useful as muscarinic receptor antagonists

Theravance, Inc. Β· Granted Tue Apr 28 2009 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 23 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7521041

Biphenyl compounds useful as muscarinic receptor antagonists

Theravance, Inc. Β· Granted Tue Apr 21 2009 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 16 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7507716

Method for treating pain with prolactin antagonists

The Board of Regents of the University of Texas System Β· Granted Tue Mar 24 2009 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 19 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7501442

Biphenyl compounds useful as muscarinic receptor antagonists

Theravance, Inc. Β· Granted Tue Mar 10 2009 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 05 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7491736

Biphenyl compounds useful as muscarinic receptor antagonists

Theravance, Inc. Β· Granted Tue Feb 17 2009 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 12 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7482470

Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders,

Jenrin Discovery, LLC Β· Granted Tue Jan 27 2009 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 22 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7479562

Biphenyl compounds useful as muscarinic receptor antagonists

Theravance, Inc. Β· Granted Tue Jan 20 2009 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 15 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7462625

Gonadotropin-releasing hormone receptor antagonists and methods relating thereto

Neurocrine Biosciences, Inc. Β· Granted Tue Dec 09 2008 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 04 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7459426

Methods of using IL-1 antagonists to treat autoinflammatory disease

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Dec 02 2008 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 27 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7456199

Biphenyl compounds useful as muscarinic receptor antagonists

Theravance, Inc. Β· Granted Tue Nov 25 2008 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 20 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7456203

Muscarinic receptor antagonists

Theravance, Inc. Β· Granted Tue Nov 25 2008 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 20 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7452865

Antagonistic analogs of GH RH (2003)

United States of America by Dept of Veterans Affairs Β· Granted Tue Nov 18 2008 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 13 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7449182

Therapeutic combination of a VEGF antagonist and anti-hypertensive agent

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Nov 11 2008 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 06 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7446108

Tri-and tetraaza-acenaphthylen derivatives as CRF receptor antagonists

Neurocrine, Inc. Β· Granted Tue Nov 04 2008 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 30 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7432304

Small molecule antagonists of Bcl-2 family proteins

THE REGENTS OF THE UNIVERSITY OF MICHIGAN Β· Granted Tue Oct 07 2008 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 02 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7427630

Condensed N-heterocyclic compounds and their use as CRF receptor antagonists

Neurocrine Biosciences, Inc. Β· Granted Tue Sep 23 2008 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 18 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7425329

Methods for treating bone cancer pain by administering a nerve growth factor antagonist

Regents of the University of Minnesota Β· Granted Tue Sep 16 2008 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 11 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7419983

Gonadotropin-releasing hormone receptor antagonists and methods related thereto

Neurocrine Biosciences, Inc. Β· Granted Tue Sep 02 2008 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 28 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7378108

Percutaneous absorption preparation of compound having angiotensin II antagonistic activit

Takeda Pharmaceutical Company Limited Β· Granted Tue May 27 2008 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 22 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7365165

IL-1 antagonist formulations

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Apr 29 2008 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 24 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7361664

Vitamin D receptor antagonists and related compositions and methods of use

The United States of America, as represented by the Department of Health and Human Services Β· Granted Tue Apr 22 2008 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 17 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7361350

Use of an IL-1 antagonist for treating arthritis

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Apr 22 2008 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 17 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7358222

Preventing airway mucus production by administration of EGF-R antagonists

The Regents of the University of California Β· Granted Tue Apr 15 2008 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 10 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

granted